BION-1301 - A Phase 1, Open-label, Single Subcutaneous Dose, Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Japanese Healthy Subjects
Latest Information Update: 13 Jan 2023
Price :
$35 *
At a glance
- Drugs Zigakibart (Primary) ; Zigakibart (Primary)
- Indications IgA nephropathy
- Focus Pharmacokinetics
- 22 Apr 2021 New trial record
- 15 Apr 2021 According to a Chinook therapeutics media release, data from this study presented during the ISN World Congress of Nephrology 2021
- 15 Apr 2021 Results published in the Chinook therapeutics Media Release